Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark completes...

    Glenmark completes phase 3 study for nasal spray

    Written by Ruby Khatun Khatun Published On 2017-12-15T10:15:58+05:30  |  Updated On 16 Aug 2021 4:19 PM IST

    New Delhi: Glenmark Pharmaceuticals said it has completed phase 3 study of its investigational fixed-dose combination nasal spray and plans to submit a new drug application with the US health regulator.


    In a BSE filing, Glenmark said it met its primary clinical endpoint in a phase 3 study evaluating the safety of Ryaltris, an investigational fixed-dose combination nasal spray, used to treat seasonal allergic rhinitis.


    Glenmark plans to "submit the company's first new drug application (NDA) to the USFDA for Ryaltris for the treatment of patients with seasonal allergic rhinitis (SAR) in the first quarter of the calendar year 2018," it added.


    The company said Ryaltris has been conditionally accepted as the brand name for GSP 301 Nasal Spray by the US Food and Drug Administration (USFDA).


    "We have worked closely with the USFDA on the clinical development programme for Ryaltris, and look forward to providing robust data to support its potential approval," Glenmark Pharmaceuticals President and Chief Medical Officer Fred Grossman said.


    This Phase 3, US-based trial was a study that enrolled 601 adults and adolescents, 12 years of age and older, with at least a two-year history of perennial allergic rhinitis.


    Patients were randomised to 52 weeks of twice-daily treatment with Ryaltris, or two different formulations of a placebo nasal spray, the filing said.

    allergic rhinitiscompletesFixed Dose CombinationFred GrossmanGlenmarkGlenmark PharmaGlenmark Pharmaceuticalsindian pharma newsInvestigationalNasal SprayNew Drug Applicationpharma newspharma news indiaphase 3 studyRyaltrisseasonal allergic rhinitisUS Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok